UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

Benzinga · 4d ago
UBS analyst Michael Yee initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $20.